Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lifestyle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,315 result(s) found for: Lifestyle. Displaying page 7 of 66.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2021-000048-23 Sponsor Protocol Number: P2-IMU-838-PMS Start Date*: 2021-11-04
    Sponsor Name:Immunic AG
    Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
    Medical condition: Progressive forms of Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    26.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004991-31 Sponsor Protocol Number: INCB24360-301/MK3475-252/Keynote252 Start Date*: 2016-05-03
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) DK (Completed) IE (Completed) ES (Completed) PL (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001694-24 Sponsor Protocol Number: D1050302 Start Date*: 2014-03-11
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...
    Medical condition: SCHIZOPHRENIA AND IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended) BG (Completed) Outside EU/EEA HU (Completed) GB (Completed) DE (Completed) PL (Completed) BE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004237-32 Sponsor Protocol Number: 70033093THR2001 Start Date*: 2019-08-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in ...
    Medical condition: Thromboembolism in subjects who have undergone an elective primary unilateral total knee replacement
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed) PT (Completed) BG (Completed) ES (Completed) GR (Completed) LT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000569-19 Sponsor Protocol Number: MK-7902-009 Start Date*: 2020-10-26
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemot...
    Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Trial now transitioned) NO (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002698-74 Sponsor Protocol Number: B7541007 Start Date*: 2020-04-01
    Sponsor Name:Pfizer Inc
    Full Title: A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO ...
    Medical condition: A phase 2b randomised, double-blind, placebo controlled dose-ranging study in Adults with Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10009888 Colitis (excl infective) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BG (Completed) SK (Completed) PL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) HU (Completed) AT (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001845-42 Sponsor Protocol Number: TAK-788-3001 Start Date*: 2020-03-02
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR...
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 20 insertion mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000397-30 Sponsor Protocol Number: Ponatinib-3001 Start Date*: 2018-10-23
    Sponsor Name:Millenium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda pharmaceutical Company Limited)
    Full Title: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelp...
    Medical condition: Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080018 Philadelphia positive acute lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FI (Completed) BG (Completed) PL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001338-24 Sponsor Protocol Number: MK-3475-669(INCB024360-304) Start Date*: 2017-12-05
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for...
    Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Temporarily Halted) PT (Trial now transitioned) AT (Prematurely Ended) HU (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002006-51 Sponsor Protocol Number: MK-3475-975 Start Date*: 2019-12-11
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (K...
    Medical condition: Esophageal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015366 Esophageal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) EE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000904-39 Sponsor Protocol Number: MK-4482-013 Start Date*: 2021-08-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection W...
    Medical condition: Prophylaxis of COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed) HU (Completed) BG (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003242-22 Sponsor Protocol Number: BCX4161-303 Start Date*: 2015-12-17
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BE (Completed) FR (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001908-42 Sponsor Protocol Number: V937-013 Start Date*: 2020-10-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors
    Medical condition: Advanced/metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) HU (Completed) DE (Completed) PL (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002034-36 Sponsor Protocol Number: V937-011 Start Date*: 2019-12-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metas...
    Medical condition: Advanced/metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004250-18 Sponsor Protocol Number: PIAII Start Date*: 2016-02-19
    Sponsor Name:Karolinska Institutet
    Full Title: Acupuncture or Metformin for Insulin Resistance in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial
    Medical condition: Polycystic ovary syndrome (PCOS) affects 10 to 15% of all women and is the most common female endocrine and metabolic disorder during the reproductive years. PCOS is characterized by anovulation, h...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    18.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000221-37 Sponsor Protocol Number: Pevonedistat-2001 Start Date*: 2016-02-22
    Sponsor Name:Millennium Pharmaceuticals, Inc. (Takeda)
    Full Title: A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplasti...
    Medical condition: Higher-risk myelodysplastic syndromes (MDS), Chronic myelomonocytic leukemia (CMML), Low-blast acute myelogenous leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054350 Chronic myelomonocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024348 Leukemia myelogenous LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024330 Leukemia acute LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067387 Myelodysplastic syndrome transformation PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IE (Completed) BG (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000972-88 Sponsor Protocol Number: MK3475-062 Start Date*: 2015-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cispla...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) LV (Completed) NL (Completed) ES (Completed) CZ (Completed) FR (Completed) AT (Completed) HU (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001290-14 Sponsor Protocol Number: EMR200136_583 Start Date*: 2014-10-24
    Sponsor Name:MERCK ROMANIA SRL
    Full Title: Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™
    Medical condition: Clinical isolated syndrome and relapse multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-009921-28 Sponsor Protocol Number: PLOTINA Start Date*: 2010-05-15
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial
    Medical condition: Breast cancer chemoprevention
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002212-16 Sponsor Protocol Number: CAIN457ADE03 Start Date*: 2015-01-22
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 03:47:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA